The Lucid M1 transcranial doppler ultrasound system has been introduced at the 9th Annual Society of Vascular and Interventional Neurology Meeting.
Earlier this month, Neural Analytics secured 510(k) clearance from the US Food and Drug Administration (FDA) for the Lucid M1 system.
The system is a battery operated medical grade tablet device, which can be easily moved across the medical facility in a range of settings that require the rapid assessment of blood flow in the brain. It allows physician to diagnose brain disorders without using more invasive tests.
Thee company also has joined the SVIN’s Mission 2020, an initiative to increase treatments for eligible patients and reduce global stroke disability.
Neural Analytics co-founder and chief science officer Robert Hamilton said: “We are pleased to support SVIN on this important initiative to improve stroke treatment worldwide and help reduce the disability associated with this condition.
“A critical component for effective stroke treatment is determining an accurate diagnosis as quickly as possible in settings inside and outside the hospital.”
Image: Lucid M1 transcranial doppler ultrasound system. Photo: courtesy of Business Wire.
